RT Journal Article
SR Electronic
T1 Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.26.21261122
DO 10.1101/2021.07.26.21261122
A1 Jeewandara, Chandima
A1 Guruge, Dinuka
A1 Pushpakumara, Pradeep Darshana
A1 Kamaladasa, Achala
A1 Aberathna, Inoka Sepali
A1 Tanussiya, Shyrar
A1 Banuri Gunasekera, B
A1 Wijesinghe, Ayesha
A1 Dissanayake, Osanda
A1 Kuruppu, Heshan
A1 Ranasinghe, Thushali
A1 Jayathilaka, Deshni
A1 Dayarathna, Shashika
A1 Ekanayake, Dinithi
A1 Jayamali, MPDJ
A1 Gamalath, Nayanathara
A1 Mudumkotuwa, Anushika
A1 Somathilake, Gayasha
A1 Dissanayake, Madhushika
A1 Harvie, Michael
A1 Nimasha, Thashmi
A1 Madusanka, Deshan
A1 Jayadas, Tibutius
A1 Wijayamuni, Ruwan
A1 Schimanski, Lisa
A1 Rijal, Pramila
A1 Tan, Tiong .K.
A1 Townsend, Alain
A1 Ogg, Graham S.
A1 Malavige, Gathsaurie Neelika
YR 2021
UL http://medrxiv.org/content/early/2021/07/28/2021.07.26.21261122.abstract
AB Introduction Due to limited access to vaccines, many countries have only administered a single dose of the AZD1222, while the dosage intervals have increased ≥ weeks. We sought to investigate the immunogenicity of a single dose of vaccine at ≥ 16 weeks.Methods SARS-CoV-2 specific antibodies in 553 individuals and antibodies to the receptor binding domain (RBD) of the Wuhan virus (WT) and the variants of concern (VOCs), ACE2 receptor blocking antibodies, ex vivo and cultured IFNγ T cell responses and B cell ELISpot responses were investigated in a sub-cohort.Results The seropositivity rates in those >70 years of age (93.7%) was not significantly different compared to other age groups (97.7 to 98.2, Pearson Chi-Square = 7.8, p-value = 0.05). The antibody titres (antibody index) significantly declined (p<0.0001) with increase in age. 18/69 (26.1%) of individuals did not have ACE2 receptor blocking antibodies, while responses to the RBD of WT (p=0.03), B.1.1.7 (p=0.04) and B.1.617.2 (p=0.02) were significantly lower in those who were >60 years. Ex vivo IFN γ T cell ELISpot responses were seen in 10/66 (15.1%), while only a few expressed CD107a. However, >85% had a high frequency of cultured IFNγ T cell ELISpot responses and B cell ELISpots.Conclusion Virus specific antibodies were maintained at ≥ 16 weeks after receiving a single dose of AZD1222, although levels were lower to VOCs, especially in older individuals. A single dose induced a high frequency of memory T and B cell responses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful to the World Health Organization, UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Prize Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002). We thank WBP, CBP, EGB and ANB for generous donations to the TJP Trust to support the production and distribution of HAT reagents.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was granted by the Ethics Review Committee of the University of Sri Jayewardenepura.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available within the manuscript, figures and the supplementary figures.All data is available within the manuscript, figures and the supplementary figures.